Details for New Drug Application (NDA): 010679
✉ Email this page to a colleague
NDA 010679 describes CANTIL, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. Additional details are available on the CANTIL profile page.
The generic ingredient in CANTIL is mepenzolate bromide. There is one drug master file entry for this compound. Additional details are available on the mepenzolate bromide profile page.
The generic ingredient in CANTIL is mepenzolate bromide. There is one drug master file entry for this compound. Additional details are available on the mepenzolate bromide profile page.
Summary for 010679
| Tradename: | CANTIL |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | mepenzolate bromide |
| Patents: | 0 |
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | 25MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
